ALLMedicine™ Lung Adenocarcinoma Center

May 21st, 2022 - To investigate the efficacy and safety of photodynamic therapy (PDT) in the treatment of choroidal metastasis. We conducted a systematic review of all reported cases of choroidal metastases treated with PDT in literature, and included the cases fr...

May 20th, 2022 - Owing to the complexities of brain metastases (BM), accurate and reliable prognostic and predictive factors remain critical roadblocks in patients with lung adenocarcinoma (LUAD) BM who undergo stereotactic radiosurgery (SRS). In total, 132 patien...

May 20th, 2022 - The aim of this study was to identify miRNAs in plasma exosomes as noninvasive biomarkers for the early diagnosis of lung adenocarcinoma (LUAD). First, exosomal miRNA profiling of three patients with early LUAD and three patients with benign lung ...

May 20th, 2022 - Not all lung adenocarcinoma (LUAD) patients with activating epidermal growth factor receptor (EGFR) mutations respond to tyrosine kinase inhibitors (TKIs) as intended. Thus, biomarkers are needed to identify patients who benefit most from EGFR-tar...

May 19th, 2022 - Immune checkpoint inhibitors are still unable to provide clinical benefit to the large majority of non-small cell lung cancer (NSCLC) patients. A deeper characterization of the tumor immune microenvironment (TIME) is expected to shed light on the ...

Feb 6th, 2018 - Purpose In response to advances in the field, the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) recently updated their recommendations ...

May 5th, 2022 - Background The standard extent of pulmonary resection for non-small cell lung cancer (NSCLC) is still lobectomy. However, recent advances in imaging technology and staging modalities and the widespread use of computed tomography (CT) screening hav...

May 4th, 2022 - The primary objective is to confirm Time on Treatment (TOT) related to afatinib treatment as first-line therapy in patients with Epidermal Growth Factor Receptor (EGFR) mutation-positive Non-Small Cell Lung Cancer (NSCLC). The observation in the r...

Mar 10th, 2022 - Under the guidance by Ottawa Decision Support Framework (ODSF), International Patient Decision Aid Standards (IPDAS) and FDA guidance for Identify what is important to patients, the investigators use semi-structured interviews qualitative research...

Feb 23rd, 2022 - The pathological lepidic growth pattern was believed to relate to the ground-glass component, whereas invasive adenocarcinoma patterns relate to the solid component. However, the solid components might be fibrosis rather tumor; and previous studie...

Feb 9th, 2022 - This is an open-label, dose-escalating Phase I study followed by a Phase 2a dose-expansion phase to study the combination of Rigosertib and Nivolumab in metastatic Kirsten rat sarcoma positive (KRAS+) lung adenocarcinoma patients who have progress...

Mar 31st, 2022 - To build on the advances that have been made in lung cancer over the past several years, researchers have their sights set on improving the efficacy of immunotherapy with novel approaches, the ability to overcome acquired resistance to targeted th...

Mar 1st, 2022 - The advent and implementation of advanced sequencing technologies in clinical practice have aided in the identification of highly active oncogenic gene fusions. RNA sequencing has illuminated the presence of NRG1 fusions, which, though rare, play ...

Feb 10th, 2022 - During the past 2 decades, the treatment of patients with lung cancer has undergone a paradigm shift, a transformation fueled by genome sequencing efforts that have revealed oncogenic driver mutations and fostered targeted drug development. Tobac...

Dec 10th, 2021 - Cisplatin is a potent antineoplastic agent derived from platinum and commonly used in the treatment of head and neck, bladder, ovarian, and testicular malignancies. 1,2 Approximately 20% of all cancer patients are prescribed platinum-based chemothe.

Nov 9th, 2021 - An increased understanding of the biology of non–small cell lung cancer (NSCLC) has led to a significant increase in therapeutic options for patients, according to Lyudmila A. Bazhenova, MD, a medical oncologist and professor of medicine at the Mo...